Industry-focused reporting highlighted that gene therapy has moved into a phase defined as much by manufacturing and safety systems as by clinical breakthroughs. The article argues that scalable production, consistent analytics, and vector engineering are now central constraints—particularly for adeno-associated virus (AAV), the dominant delivery platform. It describes how limitations emerge when programs scale from lab-scale production into larger bioreactors, requiring upgrades in both upstream vector generation and downstream purification/formulation. The piece also points to the need for more tissue-selective AAV variants to reduce reliance on high doses. For operators and developers, the discussion underscores that gene therapy platform competitiveness may increasingly hinge on process control and vector design, not only clinical readouts.